Psychiatry
Tardive Dyskinesia
Competing Theories on the Pathophysiology of Tardive Dyskinesia
Multiple theories have been proposed to explain the pathophysiology of tardive dyskinesia (TD), each contributing unique insights into this complex condition. Key hypotheses include dopamine supersensitivity, oxidative stress, and γ-aminobutyric acid (GABA) dysfunction, with other research highlighting the roles of genetic predisposition and synaptic changes. Understanding the underlying mechanisms of TD is essential for the development of targeted treatments.
The pathophysiology of TD is still not fully understood. One of the prevailing theories is the dopamine supersensitivity, or dopamine upregulation, hypothesis. This theory was developed because the drugs that have been shown to cause TD are almost exclusively agents that block the postsynaptic dopamine D2 receptor. The idea is that, when dopamine D2 receptor antagonists, such as antipsychotics, are taken for a long time, the brain tries to compensate and might create more dopamine receptors or make the existing dopamine receptors more sensitive. However, this theory does not quite fully explain everything. For example, not every patient on D2-blocking agents develops TD, and symptoms of TD may continue even when you stop the drug.
Another theory relates to oxidative stress and neurotoxicity. We know that antipsychotics can sometimes be toxic. They can generate free radicals that damage neurons, especially in the dorsal striatum, which is crucial for movement coordination. If you block those D2 receptors and upregulation happens, it might start a cascade of events. And, at some point, you might cross a threshold where the damage is done and there is no turning back.
Then there is the GABA dysfunction theory. GABA is the brain’s main inhibitory neurotransmitter, and GABA interneurons connect and regulate the firing of other neurons. If antipsychotics cause damage to the GABA interneurons, especially in the dorsal striatum, this could lead to a dysregulation of the dopamine system and the dyskinetic movements that are seen in patients with TD. Therefore, there could be both a direct and an indirect effect on dopamine pathways in the striatum.
Yet another theory on the pathophysiology of TD is the neuroplasticity and synaptic change theory. Blocking D2 receptors might lead to maladaptive synaptic plasticity, which perhaps increases presynaptic dopamine release, possibly causing damage in the synapses.
There is also a genetic component to TD that we do not fully understand yet, but we have some clues. There is probably not a single genetic abnormality that can be implicated in development, but rather a number of genes. Variations in genes that are related to dopamine and serotonin receptors, oxidative stress, and drug metabolism have been identified. The holy grail would be if we were able to perform genetic testing to predict whether a patient is more sensitive to developing TD, which could lead to different treatment choices.
Studies in primates show that it might actually be the D3 receptors and GSK3B that are upregulated in TD, not the D2 receptors. In conclusion, it is not about one theory on the pathophysiology of TD being right and the others being wrong. It could be a combination of all these factors, with different factors being more important in different people. The goal is to get to a point where we can individualize treatment based on which pathophysiology is predominant. The better we understand these mechanisms, the better we will be at developing treatments that really work—or, even better, at preventing TD from developing in the first place.
Ali Z, Roque A, El-Mallakh RS. A unifying theory for the pathoetiologic mechanism of tardive dyskinesia. Med Hypotheses. 2020;140:109682. doi:10.1016/j.mehy.2020.109682
Blanchet PJ. A focused update on tardive dyskinesia. Can J Neurol Sci. 2020;47(6):747-755. doi:10.1017/cjn.2020.131
Caroff SN. A new era in the diagnosis and treatment of tardive dyskinesia. CNS Spectr. 2022 Oct 24:4-14. doi:10.1017/S1092852922000992
Caroff SN. Recent advances in the pharmacology of tardive dyskinesia. Clin Psychopharmacol Neurosci. 2020;18(4):493-506. doi:10.9758/cpn.2020.18.4.493
Cho CH, Lee HJ. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:207-213. doi:10.1016/j.pnpbp.2012.10.018
Harrison PJ. The neuropathological effects of antipsychotic drugs. Schizophr Res. 1999;40(2):87-99. doi:10.1016/s0920-9964(99)00065-1
Takeuchi H, Mori Y, Tsutsumi Y. Pathophysiology, prognosis and treatment of tardive dyskinesia. Ther Adv Psychopharmacol. 2022;12:20451253221117313. doi:10.1177/20451253221117313
Tamminga CA, Thaker GK, Chase TN. GABA dysfunction in the pathophysiology of tardive dyskinesia. Psychopharmacology Suppl. 1985;2:122-127. doi:10.1007/978-3-642-70140-5_16
Tsermpini EE, Redenšek S, Dolžan V. Genetic factors associated with tardive dyskinesia: from pre-clinical models to clinical studies. Front Pharmacol. 2022;12:834129. doi:10.3389/fphar.2021.834129